Search Results

Three-Year Neuroguard IEP PERFORMANCE II Data Presented

March 13, 2026—Three-year outcomes from the PERFORMANCE II trial studying the Neuroguard Integrated Embolic Protection (IEP) 3-in-1 Carotid Stent System were presented by William A. Gray, MD, at the International Symposium on Endovascular Therapy (ISET).

Baylis Medical's All-in-One VersaCross Transseptal Solution Used in MitraClip Procedure

September 23, 2019—Baylis Medical Company, Inc. announced the first MitraClip procedure performed using the company’s VersaCross transseptal solution.

Radiaction Establishes Medical Advisory Board

August 13, 2024—Radiaction Medical, Ltd, an Israel-based medical device company founded by Amir Belson, MD, announced the formation of its United States medical advisory board (MAB).

Vivasure’s PerQseal Closure Device Evaluated in Initial Results From PATCH Pivotal Study

November 3, 2024—Vivasure Medical recently announced initial positive results from its PATCH pivotal study conducted in the United States under an investigational device exemption, evaluating the safety and efficacy of the Vivasure PerQseal closure device system.

No Excess Mortality Risk Found in Paclitaxel-Coated Devices, Concludes FDA

July 11, 2023—The FDA has determined that the totality of available data and analyses does not support an excess mortality risk for paclitaxel-coated devices, according to the letter issued to health care providers informing them of updated information regarding paclitaxel-coated devices used to treat peripheral arterial disease (PAD).

CREST-2 Shows Reduced Stroke Risk With Carotid Artery Stenting Plus Intensive Medical Management; No Added Benefit Seen With CEA

November 21, 2025—In a pair of randomized, observer-blinded clinical trials designed to evaluate optimal management of asymptomatic carotid stenosis, Brott et al found that carotid artery stenting (CAS) added to intensive medical therapy significantly reduced stroke risk compared with medical therapy alone, while carotid endarterectomy (CEA) offered no significant additional benefit.

CMS Proposes Coverage Expansion for Carotid Artery Stenting

July 13, 2023—The Centers for Medicare & Medicaid Services (CMS) released a decision memo proposing expanded coverage for percutaneous transluminal angioplasty (PTA) of the carotid artery concurrent with stenting (CAS), including that coverage of the procedure is reasonable and necessary with the placement of an FDA-approved carotid stent with an FDA-approved or FDA-cleared embolic protection device, for Medicare beneficiaries under specified conditions.

Conformal CLAAS System’s Thrombogenicity Evaluated in Comparative Study

March 19, 2024—Conformal Medical, Inc. recently announced that findings from an in vitro study comparing the relative thrombogenicity of the company’s CLAAS left atrial appendage occlusion (LAAO) implant to the Watchman FLX device (Boston Scientific).

Conformal Medical’s CLAAS LAAO Device Evaluated in Published Preclinical Study

January 5, 2023—Conformal Medical, Inc., which is developing next-generation left atrial appendage occlusion (LAAO) technology, announced the publication of a preclinical study of the company’s CLAAS LAAO device in a healthy canine model.

Vivasure Medical PerQseal+ Evaluated in United States Early Feasibility Study for Large-Bore Closure

March 15, 2022—Vivasure Medical, an Ireland-based developer of fully absorbable percutaneous vessel closure technology, announced that the first patient was treated in a United States early feasibility study evaluating the PerQseal+.

Conformal Medical Presents Early Feasibility Study Results for LAA Assessment

February 27, 2023—Conformal Medical, Inc. announced the presentation of results from the CONFORMAL early feasibility study, which is evaluating the use of angiography compared to transesophageal echocardiogram (TEE) for left atrial appendage (LAA) assessment.

Early Studies Presented for Conformal Medical CLAAS Left Atrial Appendage Closure Technology

October 15, 2020—Conformal Medical, Inc. announced that clinical data from two first-in-human studies of the company's next-generation CLAAS left atrial appendage closure (LAAC) technology were presented in two abstracts by Vivek Reddy, MD, and William Gray, MD, at TCT Connect, the 32nd annual Transcatheter Cardiovascular Therapeutics scientific symposium of the Cardiovascular Research Foundation held online October 14-18, 2020.

Vivasure Commences Pivotal PATCH Study of PerQseal Closure Device System

May 2, 2023—Vivasure Medical, an Ireland-based company developing fully absorbable technology for percutaneous vessel closure, announced it has commenced the company’s PATCH pivotal study, which is evaluating the safety and efficacy of the Vivasure PerQseal closure device system.